NCT06357507 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bernhard S, Spaniol V, Aebi C
Molecular pathogenesis of infections caused by Moraxella catarrhalis in children. Swiss Med Wkly. 2012 Oct 29;142:w13694. doi: 10.4414/smw.2012.13694. eCollection 2012.
Blakeway LV, Tan A, Peak IRA, Seib KL
Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development. Microbiology (Reading). 2017 Oct;163(10):1371-1384. doi: 10.1099/mic.0.000523. Epub 2017 Sep 12.
Sethi S, Murphy TF
Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008 Nov 27;359(22):2355-65. doi: 10.1056/NEJMra0800353. No abstract available.

Molecular Characterization of Moraxella Catarrhalis Isolates From Pneumonic Children at Pediatric Assiut University Hospital

Clinical trial NCT06357507 - References